Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Quoin advances its U.S. patent protection with allowed claims supporting QRX003's investigational approach to treating Netherton Syndrome.
Quoin advances its U.S. patent protection with allowed claims supporting QRX003's investigational approach to treating Netherton Syndrome.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.